TriunityCX built Trisana to close that gap, at no cost to health systems, generating evidence that pharmaceutical companies need and cannot get anywhere else.
The 90 days after discharge is the highest-risk window in the patient journey. It is also the window where both health systems and pharmaceutical companies lose the signal entirely.
The Hospital Readmissions Reduction Program penalizes facilities for excess readmissions in heart failure, COPD, pneumonia, and other high-burden conditions. The average penalized hospital loses approximately $217,000 per year. For FY 2027, CMS changes are projected to penalize 75 to 82 percent of all hospitals. The passage of the One Big Beautiful Bill compounds this pressure, introducing an estimated $1 trillion in Medicaid cuts over the next decade with more than 300 rural hospitals at immediate risk of closure.
Pharmaceutical companies building real-world evidence frameworks for market access and payer strategy are working with data that captures what was billed and what was dispensed, not what the patient actually experienced. Claims data arrives weeks or months after the clinical window has closed. It does not capture why a patient stopped taking their medication, what social barrier prevented a follow-up appointment, or how the patient's confidence in managing their condition changed across the weeks following discharge.
A two-sided health technology platform connecting health systems, patients, and pharmaceutical companies through a shared post-discharge patient management infrastructure.
TriunityCX case managers conduct structured patient contact at defined intervals across the post-discharge window, collecting medication adherence data, SDOH barrier information, self-efficacy scores, and follow-up appointment status in real time. The platform classifies each patient and surfaces the cases requiring immediate attention. Hospitals receive monthly executive reports showing financial impact in readmission penalty avoidance. There is no subscription fee, no implementation cost, and no change to clinical workflows.
Learn how Navara works →Lumaris gives pharma market access and health economics teams access to High-Fidelity Patient Evidence, the structured behavioral and social evidence generated through the Navara protocol. HFPE is prospective, patient-sourced, and collected during the highest-risk post-discharge window. It captures medication adherence velocity, individual-level SDOH barriers, self-efficacy trajectory, follow-up status, and clinical profile at structured intervals across 90 days.
Learn how Lumaris works →A patient is discharged from a hospital partner and enrolled in the Navara protocol with their verbal consent. TriunityCX case managers take responsibility for the 90-day post-discharge engagement from that point forward, with no action required from hospital clinical staff.
Case managers contact the patient at defined intervals across the 90-day window, collecting direct data on medication adherence, social barriers, self-efficacy, and follow-up status. The platform classifies each patient by risk level in real time. Hospital leadership receives a monthly executive report automatically.
De-identified evidence from patient interactions flows into Lumaris, where pharmaceutical partners access aggregate cohort analytics, adherence trajectory data, SDOH barrier distributions, and novel evidence outputs unavailable from any other real-world data source. That subscription revenue funds Navara's operations.
That payment funds the case management operations that keep Navara free for hospitals. And the hospital program generates the patient volume that makes the pharmaceutical evidence meaningful. Each part of the model reinforces the others. This alignment is not incidental. It is the structural foundation of everything TriunityCX builds.
Structured data collection drops sharply after the first two weeks following discharge. Claims data thins. EHR entries stop. The gap occurs precisely during the window when adherence failure and readmission risk are highest. Trisana closes it.
Whether you are a health system administrator exploring post-discharge patient management solutions, a pharmaceutical professional interested in a new category of real-world evidence, or an investor or collaborator interested in what TriunityCX is building, we welcome the conversation.